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ABSTRACT
Monoamine oxidase inhibitors (MAO-I) belong to the earliest drugs tried in 
Parkinson’s disease (PD). They have been used with or without levodopa (L-DOPA). 
Non-selective MAO-I due to their side-effect/adverse reaction profile, like tranylcypromine 
have limited use in the treatment of depression in PD, while selective, reversible MAO-A 
inhibitors are recommended due to their easier clinical handling. For the treatment of 
akinesia and motor fluctuations selective irreversible MAO-B inhibitors selegiline and 
rasagiline are recommended. They are safe and well tolerated at the recommended 
daily doses. Their main differences are related to (1) metabolism, (2) interaction with 
CYP-enzymes and (3) quantitative properties at the molecular biological/genetic level. 
Rasagiline is more potent in clinical practise and has a hypothesis driven more 
favourable side effect/adverse reaction profile due to its metabolism to aminoindan. 
Both selegiline and rasagiline have a neuroprotective and neurorestaurative potential.  
A head-to head clinical trial would be of utmost interest from both the clinical outcome 
and a hypothesis-driven point of view. Selegiline is available as tablet and melting 
tablet for PD and as transdermal selegiline for depression, while rasagiline is marketed 
as tablet for PD. In general, the clinical use of MAO-I nowadays is underestimated. 
There should be more efforts to evaluate their clinical potency as antidepressants and 
antidementive drugs in addition to the final proof of their disease-modifying potential. In 
line with this are recent innovative developments of MAO-I plus inhibition of acetyl-
choline esterase for Alzheimer’s disease as well as combined MAO-I and iron chelation 
for PD.
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INTRODUCTION
Monoamine oxidase (MAO) is an important enzyme 
to  metabolize  in  vivo  endogenous  and  diet-derived 
biogenic  amines  via  oxidative  deamination.  Major 
substrates are noradrenaline, adrenaline, dopamine, 
β-phenylethylamine  (PEA)  and  serotonin.  These 
substrates  are  underlying  in  the  biochemical  patho-
logy  of  “depression”  and  Parkinson’s  disease  (PD). 
The deficiency of serotonin, noradrenaline and dopa-
mine builds-up the  hypothesis of  “depression” while 
a  loss  of  dopamine,  noradrenaline  and  serotonin  is 
the  biochemical  basis  of  degenerative  processes 
underlying  PD.  Therefore,  supplementation  of  defi-
cient biogenic amine neurotransmitters with 3,4-dihydroxy-2 Peter  Riederer
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phenylalanin  (L-DOPA)  has  been  established  as 
early  as  the  late  50
th  and  early  60
th  of  the  last 
century  including  the  use  of  MAO-inhibitors.  This 
class  of  psychopharmacological  active  compounds 
inhibits  the  break-down  of  biogenic  amine  neuro-
transmitters and thus increase their concentration in 
the  synaptic  cleft  and  at  respective  postsynaptic 
receptor  sites.  A  mood  elevating  effect  in  patients 
with tuberculosis after treatment with iproniazid was 
first  described  by  Kline  (1958).  In  PD  the  first 
reports were published by Sano (1960; Foley et al., 
2000) using iproniazid and pheniprazine alone or in 
combination  with  D,L-DOPA  in  a  small  number  of 
patients, Degkwitz et al. (1960), who used iproniazid 
in combination with L-DOPA and in reserpin treated 
patients with schizophrenia and Birkmayer, Hornykiewicz 
and  Bernheimer,  who  tried  a  variety  of  compounds 
like harmine, isocarboxazid and other MAO-I’s (Bern-
heimer  et  al.,  1961;  Birkmayer  and  Hornykiewicz 
1961;  1962;  1964)  alone  or  in  combination  with  L- 
DOPA  in PD.  The effects  were mild  or  not existing 
when  these  MAO-I  were  given  alone.  However  all 
theses  early  reports  agree  that  MAO-I  potentiated 
the  effect  of  (D),  L-DOPA  but  intensified  also 
adverse  reactions.  Further  examination  and  post 
mortem  studies  gave  evidence  that  MAO-I  given 
shortly  before  patients  deaths  were  restoring  the 
levels  of  noradrenaline  and  serotonin  with  no 
significant  effect  on  the  concentration  of  brain 
dopamine  (Bernheimer  et  al.,  1962;  1963).  This 
data  pointed  to  a  combination  therapy  of  L-DOPA 
and  MAO-I  already  in  the  early  60
th  of  the  last 
century. An extensive description of detailed historical 
aspects  of  MAO  and  its  inhibitors  is  given  in  the 
excellent overview on treatment strategies in PD by 
Foley  (2001).  A  further  break-through  was  the  dis-
covery  of  multiple  forms  of  MAO,  MAO-A  and 
MAO-B,  by  Johnston  (1968).  MAO-A  deaminates 
especially  serotonin,  noradrenaline  and  tyramine 
and is inhibited selectively at low concentrations (μM) 
of clorgyline while MAO-B is insensitive to clorgyline 
and in the human brain desaminates PEA and to a 
high  degree  dopamine  (Glover  et  al.,  1977).  The 
first  selective  MAO-B-I  was  L-deprenyl  (E-250, 
L-deprenyl,  selegiline),  synthezised  by  Zoltan  Ecseri 
in  1962,  patented  as  antidepressant  in  1965,  1966 
and  developed  by  Jozsef  Knoll  as  “psychic 
energizer  (Knoll  et  al.,  1965).”  The  combination  of 
selegilines  selective  MAO-B-I  properties  and  the 
short-lasting  stimulant  effect  of  one  of  its  meta-
bolites, metamphetamine, (later proved to be also a 
reversible  MAO-inhibitor  see  also  Foley  2001  for 
details  of  such  early  developments)  was  indeed  a 
concept  to  put  forward  new  antidepressant  agents 
(Varga  and  Tringer,  1967).  Knoll  mentioned  in  his 
1965  publication  that  selegiline  does  not  increase 
motility  and  lowers  blood  pressure  in  experimental 
animals. Using tyramine (a MAO-A and -B substrate) 
it  became  evident  that  selegiline  antagonizes  the 
socalled “cheese-effect” (increase of blood pressure 
noteable  especially  after  consumption  of  larger 
amounts of cheese in patients treated with unselective 
or  MAO-A-inhibitors)  (Knoll  and  Magyar,  1972).  As 
dopamine  in  rodent  brain  is  s  preferred  MAO-A 
substrate  an  effect  of  MAO-inhibitors  on  motility 
(see above) has not been observed. PD, therefore, 
was not the focus for using MAO-B-I as therapeutic 
strategy. The suggestion in late 1974 for selegilines 
use  in  PD  and  especially  in  treating  ON-OFF 
symptoms  by  one  of  use  (PR)  was  based  on  (1) 
the early and in principle beneficial effects of MAO-I 
when  combined  with  L-DOPA  (see  above),  (2)  the 
effects  of  selegiline  in  antagonizing  the  cheese- 
effect  and  (3)  the  possibility  that  dopamine  in 
humans  might  well  be  a  substrate  for  MAO-B. 
Convincing Moussa Youdim about using selegiline for 
a  first  trial  in  PD  patients  in  PD  he  agreed  to 
provide  Walther  Birkmayer  and  myself  (P.R.)  with 
some grams of selegiline that he had obtained from 
Josef Knoll. The trial was showing a beneficial effect 
in the symptomology of PD (Birkmayer et al., 1975; 
1977; Foley, 2001; for historical notes see Riederer 
2004; Youdim, 2006). Later (Birkmayer et al., 1983; 
1985)  we  provided  evidence  for  selegiline  having 
neuroprotective action, a concept that is still followed 
and  seems  to  be  proven  by  the  follow-up  pro-
pargylaminoderivative  rasagiline  as  shown  recently 
in  the  ADAGIO-study  (Olanow  et  al.,  2008;  2009).
    The  innovating  basic  research  and  beneficial 
actions  of  selegiline  in  PD  were  responsible  for 
intensive  MAO-I  drug  developments  for  both  PD 
and  “depression”.  In  this  review  we  present  the 
major  compounds  currently  being  used  as  well  as 
an  outlook  of  further  such  developments. MAO-I  in  Parkinson’s  Disease 3
Table  1.  Monoamine  oxidase  inhibitors
Drug Metabolites Trials  in  humans Galenic  forms
    Selegiline Desmethylselegiline AD,  DEP,  PD Tablet,  transdermal,  melting  tablet
p-Hydroxydesmethylselegiline
Selegiline-N-oxide
L-Amphetamin
L-Metamphetamin
p-Hydroxyamphetamine
p-Hydroxymetamphetamine
    Rasagiline Aminoindan PD Tablet
As  reviewed  by  Magyar  et  al.,  2010;  Weinreb  et  al.,  2010;  Naoi  and  Maruyama,  2010.
MAO-I  in  clinical  practise
    Monoamine  oxidase  (MAO)  inhibitors  (MAOIs)  at 
present  can  be  classified  into  3  types:
ㆍOlder,  irreversible  nonselective  agents  such  as 
phenelzine  and  tranylcypromine
ㆍIrreversible,  selective  drugs  (MAO-B-I’s)  such 
as  selegiline  and  rasagiline
ㆍReversible,  selective  MAO-A  inhibitors  (RIMAs 
= reversible inhibitors of MAO-A) such as moclo-
bemide  (Overviews:  Szelenyi  1993;  Laux  et  al., 
1995)
  O v e r v i e w  o f   M A O I s :
    Iproniazid Non-selective,  irreversible
    Isocarboxazid Non-selective,  irreversible
    Moclobemide MAO-A  selective,
reversible  (RIMA)
    Nialamide Non-selective,  irreversible
    Pargyline MAO-B  selective,  irreversible
    Phenelzine Non-selective,  irreversible
    Rasagiline MAO-B  selective,  irreversible
    Safrazine Non-selective,  irreversible
    Selegiline MAO-B  selective,  irreversible
    Toloxatone MAO-A  selective,
reversible  (RIMA)
    Tranylcypromine Non-selective,  irreversible
    The clinical indications and efficacy of the MAOIs 
are  established  for  disorders  as  follows:
  ㆍParkinson’s  disease  (PD)
  ㆍDepressive  disorders
  ㆍAnxiety disorders (social phobia, panic disorder, 
PTSD)
    Other  potential  therapeutic  uses  and  indications 
can  be  smoking  cessation,  attention  deficit  hyper-
activity  disorder  and  cognitive  deficits  in  dementia 
for  moclobemide  (Chan-Palay,  1992;  Berlin  et  al., 
1995).
INDICATIONS  IN  PARKINSON’S  DISEASE
Treatment  of  motor  symptoms
    Both, selegiline and rasagiline (Table 1) are bene-
ficial  in  treating  motor  symptoms  in  PD  as  mono-
therapy  and  in  combination  with  L-DOPA  and  a 
decarboxylase inhibitor. Rasagiline is more effective 
in  this  regard  as  shown  also  in  the  daily  dosis 
necessary  for  a  symptomatic  effect:  5∼10  mg/day 
selegiline, 1 mg/day rasagiline. Long-term trials with 
selegiline point to the fact that 30∼40% of the daily 
L-DOPA  dosis  can  be  spared  when  combined  with 
the  MAO-B-I  (Szeleny,  1993;  Lees  et  al.,  1995; 
Myllylä  et al., 1997). It is not far-fetched to assume, 
that PEA, which increases after selegiline treatment 
in  brain  tissue  (Reynolds  et  al.,  1978)  and  by  this 
exerts dopamine release-promoting properties, contri-
butes  to  dopamine’s  behavioural  effects  including 
improvement of motility (Foley, 2001; Gerlach et al., 
2007;  Riederer,  2009).
    There  is  overwhelming  evidence  that  selegiline 
has  beneficial  effects  on  motoricity  and  motorfluc-
tuations  as  shown  already  in  the  first  clinical  trial 
(Birkmayer  et  al.,  1975)  and  in  follow-up  clinical 
studies  as  summarized  by  Gerlach  et  al.  (2007).
    Rasagiline effects on motoricity are even stronger 
as  shown  by  the  TEMPO-(Parkinson  Study  Group, 
2002;  2004),  PRESTO-  (Parkinson-Study-Group, 
2005),  LARGO-  (Rascol  et  al.,  2005)  and  ADAGIO- 
(Olanow  et  al.,  2008;  2009)  studies.
    In  all  these  and  additional  clinical  studies  (eg 
Rabey  et  al.,  2000;  Thebault  et  al.,  2004;  Rascol, 4 Peter  Riederer
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Table  2.  Nueroprotection  in  Parkinson's  disease  by  selegline  (prospective,  randomized,  double-blind,  placebo-controlled  studies)
Autuors  (year) Name  of  the  study  N Result
Tetrud  and  Langston  (1989) Pilot  study  for   44 Endpoint  (levodopa)
  DATATOP Placebo  312.1  d
Selegiline  548.9  d
Parkinson  Study  Group DATATOP 800 Endpoint  (levodopa)
  (1989a,  b,  1993) After  12  months:
Placebo  47%
Selegiline  26%
Myllylä  et  al.  (1992) Finnish  trial   47 Endpoint  (levodopa)
Placebo  372±28  d
Selegiline  545±94  d
Allain  et  al.  (1993) French  Selegiline    93 Endpoint  (levodopa)
  multicenter  trial After  3  months:
Placebo  18.4%
Selegiline  4.5%
Olanow  et  al.  (1995) SINDER 101 Deterioration  in  UPDRS  between  baseline  and  final  visit
  (14  months)
Placebo  −5.8±1.4  points
Selegiline  −0.4±1.3  points
przuntek  et  al.  (1999) SELEDO 116 Primary  end  point:  need  for  ＞50%  increase  in
  levodopa  dose
Placebo  2.6  years
Selegiline  4.9  years
Larsen  et  al.  (1997,  1999) 163 Patients  treated  with  levodopa＋selegiline  developed
  markedly  less  severe  parkinsonism  (not  statistically
  significant)  and  required  lower  doses  of  levodopa＋placebo.
Myllylä  et  al.  (1992)   52 Endpoint  (levodopa)  after  two  years
Placebo  545±90  d
Selegiline  372±28  d
Myllylä  et  al.  (1997)   44 Levodopa  dose  (5  years):
Placebo  725±78  mg/d
Selegiline  405±59  mg/d
From  Riederer  and  Lachenmayer  2003.
2005;  Biglan  et  al.,  2006;  Siderowf  and  Stern, 
2006)  it  could  be  shown  that  rasagiline  is  well 
tolerated, safe, improves motor symptoms, prevents 
motor complications in PD, has beneficial effects on 
quality  of  life  parameters,  is  effective  as  mono-
therapy  or  in  adjunctions  to  L-DOPA-therapy,  is 
beneficial  in  early  and  late  stages  of  PD,  is  safe 
when combined with all other PD-relevant therapies 
including  COMT-inhibitors  and  may  have  disease- 
modifying  properties.
Neuroprotection  and  disease-modification
    Selegiline  and  rasagiline  are  “suizide-inhibitors” 
which  inhibit  the  enzyme  irreversibly  and  for  a 
rather  long  time.  Therefore  only  newly  synthesized 
enzyme will recover MAO activity sufficient to meta-
bolize its substrates in an adequate amount. Positron- 
emission  tomography  (PET)  studies  have  shown  a 
biological  half-life  time  (HLT)  of  MAO-B  recovery 
after  selegiline  -  (Fowler  et  al.,  1994)  or  rasagiline- 
(Freedman  et  al.,  2005)  induced  blockade  of  about 
30∼40  days.  As  described  earlier  (Riederer  and 
Lachenmayer,  2003;  Gerlach  et  al.,  2007)  PET- 
studies  are  only  in  part  suitable  to  detect  the  HLT 
of  MAO-inhibitors  as  they  only  detect  the  distri-
bution  of  radiolabeled  inhibitor  and  its  metabolites. 
In  addition  the  exact  kinetic  properties  underlying 
these  PET-studies  have  been  described  only  at 
random  (Arnett  et  al.,  1987).  In  contrast,  measure-
ment  of  PEA,  the  pure  MAO-B  substrate,  in  the 
urine  of  healthy  individuals  after  selegiline  dosing 
showed recovery (decline) of this amine concentration 
to normal values already 2∼3 days after withdrawal 
of  selegiline  (Clarke  et  al.,  2001).  Such  data  agree 
with  other  pharmacological  studies  as  described  by 
Riederer  and Lachenmayer  (2003) and  point to  the MAO-I  in  Parkinson’s  Disease 5
Table  3.  Datatop  follow-up-clinical  studies
N
    Parkinson  Study  Group  (1996a) ㆍ310  of  originally  800
ㆍNo  levodopa  necessary  for  the  first  21±4  month
ㆍPatients remained blind regarding selegiline and tocopherol and received 10 mg selegiline per day
189  on  selegiline,  earlier  need  for  levodopa
121  without  selegiline,  later  need  for  levodopa
Result:  loss  of  selegilines  efficacy?
    Shoulson  et  al.  (2002) Patients  of  DATATOP  with  levodopa  plus  selegiline  treatment  for  seven  years  were  included
Patients  that  received  placebo  after  three  to  five  years  treatment  with  selegiline  were  included
Results:  improvement  of  ON-OFF  fluctuations  and  motoricity  in  the  selegiline’s  treated  group
Less  dyskinesias  in  the  placebo  group
conclusion  that  the  HLT  of  MAO-B  recovery  after 
irreversible  inhibition  by  selegiline  is  about  7  days. 
According  to  Green  et  al.  (1977)  an  80%  inhibition 
of  MAO-isoenzymes  is  necessary  to  increase  con-
centration  of  biogenic  amines  significantly.  This 
means that newly synthesized enzyme in the range 
of  20  to  30%  is  sufficient  to  lose  any  symptomatic 
behavioural  effect  after  withdrawal  of  any  MAO- 
inhibitor. In line with this are studies by Youdim and 
Tipton  (2002)  who  could  not  detect  selegiline- 
induced stereotyped behaviour due to PEA increase 
4  days  after  withdrawal  of  selegiline.  At  this  time 
MAO-B  recovery  was  already  20%.  Taking  these 
findings  into  account  a  wash-out  phase  of  two 
weeks  or  after  selegiline/rasagiline  withdrawal  is 
sufficient  to  avoid  any  symptomatic  effect  of  these 
MAO-I’s.  Therefore,  the  interpretations  of  the 
DATATOP-study  and  other  follow-up  trials  to 
demonstrate  a  “neuroprotective”  effect  have  to  be 
reconsidered.  If  so,  a  neuroprotective  effect  of 
selegiline  cannot  be  excluded  (Riederer  and 
Lachenmayer,  2003;  Gerlach  et  al.,  2007).  Table  2 
(taken in part from Riederer and Lachenmayer 2003 
with  permission)  illustrates  the  major  outcomes  of 
the  most  important  clinical  long-term  trials  with 
selegiline.  While  treatment  of  patients  in  an  early 
phase of PD with selegiline shows sufficient results 
regarding  motoricity  and  disease-modification  the 
unconclusive  results  of  the  DATATOP-follow-up 
clinical  trials  may  demonstrate  a  bias  in  severity  of 
patients  grouping  as  given  in  the  first  follow-up 
study  (Parkinson  Study  Group,  1996a)  or  that  the 
patients  have  non-response  based  on  disease- 
progression  and/or  accompanying  diseases  (Table 
3).  As  there  were  no  final  conclusions  about  the 
neuroprotective  effect  of  selegiline  the  development 
of  more  efficient  clinical  trial  designs  have  been 
investigated  including  PET-controlled  studies  as 
shown  with  dopaminergic  agonists.  More  recently 
the “delayed-start study design” has been developed 
as  discussed  by  D’Agostino  (2009).  Rasagiline  has 
been  the  first  drug  tested  in  such  clinical  trial.  In 
fact  the  ADAGIO-study  has  given  profound  evi-
dence  for  a  disease-modifying  effect  of  1  mg/day 
rasagiline,  while  there  was  not  such  benefit  at  a  2 
mg/day  dosis  (Table  4).  Although  -  and  in  com-
parison  to  the  negative  outcome  of  a  delayed- 
start-study with pramipexol (Schapira et al., 2009) - 
there  is  ample  evidence  for  a  significant  disease- 
modification  with  low  dosis  rasagiline  this  clinical 
outcome  has  been  questioned  recently  (Ahlskog 
and  Uitti,  2010;  Sampaio  and  Ferreira,  2010; 
Schwarzschild,  2010).  Caslake  et  al.  (2009) 
conclude in their Cochrane Database report: “MAO-B 
inhibitors  are  one  option  for  the  early  treatment  of 
PD although they have weaker symptomatic effects 
than  levodopa  and  dopamine  agonists.  They  may 
reduce the rate of motor fluctuations compared with 
initial  levodopa  therapy  and  may  have  fewer 
significant  adverse  effects  than  the  older  agonists 
but  data  are  too  few  to  provide  reliable  con-
clusions”.
    Neuroprotective,  neurorestaurative  and  disease- 
modifying  effects  of  selegiline  and  rasagiline  are 
substantiated  by  in  vitro-as  well  as  in  vivo  experi-
mental  studies  (Table  5).  There  is  ample  evidence 
that  compounds  attached  to  a  propargylamino 
group induce molecular processes which act against 
cell  death  mechanisms  like  apoptosis,  excitotoxicity 
and  oxidative  stress.  These  are  non-MAO  based 
mechanisms  and  they  act  not  only  on  a  functional 
level  but  rather  on  influencing  gene  expression and 6 Peter  Riederer
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Table  4.  Summary  of  rasagiline  clinical  studies
Study Design* Duration
Rasagiline
therapy
No. 
patients
Primary
outcome
Principle  secondary 
outcomes
Monotherapy  for  early  Parkinson's  disease  (Hoehn  &Yahr  stage≤3)
  Stern  et  al.  (2004)
  ( P h a s e  I I )
  Parkinson  Study  Group
    (2002)  (TEMPO)
    (Phase  III)
  Parkinson  Study  Group
    (2004)  (TEMPO
    delayed-start,
    active-treatment  phase)
    (Phase  III)
Placebo-controlled
Placebo-controlled
Delayed-start  (see
  adove  row  for
  initial  6  month
  placebo-controlled
  phase)
10  weeks
 6  m o n t h s  
12  months
1 ,  2  o r
 4  m g / d a y
1  or  2
 m g / d a y
1  or  2  mg/day 
 ( 1 2  m o n t h s ) ,  o r
 2  m g / d a y  a f t e r
  6 months placebo
 5 6
404
380
  Safety  and
    tolerability
  Efficacy
    (UPDRS-Total)
  Efficacy
    (UPDRS-Total)
 U P D R S ,  C G I
 U P D R S  s u b s c a l e s
    (Mental,  ADL,  motor)
 U P D R S  s u b s c a l e s
    (Mental,  ADL,  motor)
Adjunct  therapy  for  advanced  Parkinson's  disease  (Hoehn  &  Yahr  stage＜5)
  Rabey  et  al.  (2000)
  ( P h a s e  I I )
  Parkinson  Study  Group
  ( 2 0 0 5 )  ( P R E S T O )
    (Phase  III)
  Rascol  et  al.  (2005)
    (LARGO)  (Phase  III)
Placebo-controlled
Placebo-controlled
Placebo-controlled
 p l u s  a n  a c t i v e
 c o m p a r a t o r
  (entacapone 200 mg
  with  each  levodopa
 d o s e )
12  weeks
 6  m o n t h s
18  weeks
0 . 5 ,  1  o r
 2  m g / d a y
0.5  or  1
 m g / d a y
1  mg/day
 7 0
472
687
  Safety  and
    tolerability
  Efficacy  (Total
    daily  OFF  time)
  Efficacy  (total
    daily  OFF  time)
UPDRS,  CGI,  levodopa
 d o s e
CGI,  UPRDS-ADL  OFF,
  UPRDS-Motor ON, PD-
 Q U A L I F
CGI,  UPDRS-ADL  OFF,
  UPDRS-Motor  On
*All  studies  were  randomised,  multi-centre,  parallel-group  and  double-blind.
ADL: activities of daily living, CGI: clinical global impressions scale, LARGO: lasting effect in adjunct therapy with rasagiline given once 
daily, OFF: poor symptom response, ON: good symptom reponse, PD-QUALIF: parkinson's disease quality of life, PRESTO: Parkinson's 
rasagiline efficacy  and safety in  the treatment of OFF,  TEMPO: trial  of  etanercept  and  methotrexate with radiographic  patient outcomes, 
UPDRS-ADL:  unified  parkinson's  disease  rating  scale-activities  of  daily  living.  From  Rascol  2005.
Table  5A.  Actions  of  propargylamine  derived  MAO-B-I
    Antagonise  MPTP,  MPP
＋,  6-OHDA
DSP4 
AF64  A 
Excito  toxins
Ischemia
    Antiapoptotic  eg.  Bcl-2  increase
    Prevention  of  mPT  in  isolated  mitochondria 
    Gene  induction  of  Bcl-2,  NFT’s
    APP  processing  inhibition 
    SEL  RAS  potentiate  PEA  behavioural  response
As  reviewed  by  Magyar  et  al  2010,  Weinreb  et  al  2010,  Naoi 
and  Maruyama  2010.
Table  5B.  Non-MAO  related  actions  of  selegiline  and  rasagiline 
on  molecular  paramters  in  vitro
SEL CNTF-,  NGF-,  BDNF-,  GDNF-mRNA
Bcl-2-,  Trx-1-,  Prx1-,  HO-1-,  TrxRx1-,  γ-GCS
DAT  increase  (but  not  after  rasagiline,  nomifensine, 
clorgyline  and  amphetamine)
Suppression  of  Aβ aggregation
RAS Bcl-2-,  BDNF-,  GDNF-, BcL-xL-,  Bcl-w-,  PKCα and ε- 
mRNA
Bcl-2-,  Bcl-xL-,  GDNF-protein
As  reviewed  by  Magyar  et  al  2010,  Weinreb  et  al  2010,  Naoi 
and  Maruyama  2010.
protein synthesis. These more recent discoveries are 
in line with the earlier assumption of neuroprotective/ 
neurorestaurative/disease-modifying  properties  espe-
cially  of  this  chemical  class  of  compounds.
Depression  in  PD
    With a prevalence of approximately 40% depression 
is  considered  to  be  the  most  frequent  psychiatric 
manifestation  in  PD  (Burn,  2002;  McDonald  and 
DeLong,  2003;  Veazey  et  al.,  2005).  Particular 
clinical  features  of  the  depressive  symptom  profile 
in patients  with  PD have  been described (Wermuth 
and Bech, 2006; Brand et al., 2007) and recommen-
dations  towards  better  recognition  given  (Burn 
2002).  About  50%  of  the  patients  meet  the  criteria 
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Table  5C.  Non-MAO  related  actions  of  selegiline  and  rasagiline 
on  molecular  parameters  in  vivo
    SEL Increase  of  GDNF-,  BDNF-,  CDNF  mRNA 
Increase  of  GPx-,  SOD-,  catalase
    activities,antioxidative  capacity,  thioredoxin
Increase  of  s  APPα secretion
Decreases  cell-cell  adhesion
Antagonizes hyperpermeability of  vascular endothelial
  c e l l s
Increase  of  life  span  in  low  dosis
Re-uptake inhibitor Increase in dopamine release after
    chronic  treatment
Dopamine  potentiation
    RAS BDNF-,  14-3-3  γ m R N A  a n d  p r o t e i n
Rin-,  Ras-,  AF6-,  SOS-,  ShcC-mRNA 
Aβ-processing  activities,  inhibition  of  holo  APP
    protein  increase 
PRDX2,  14-3-3γ mRNA 
Dopamine  release  (chronic  rasagiline)
As  reviewed  by  Magyar  et  al  2010,  Weinreb  et  al  2010,  Naoi 
and  Maruyama  2010.
Table 6. Randomised, double-blind controlled studies with tranylcypromine (TCP) in the treatment of  depressive disorders  (from Laux 
et  al.,  2002)
Study/Reference N
TCP-Dosage
(mg/day)
Duration  (wk) Results
  v s .  I m i p r a m i n  ( I )
        Freyhan  (1960) 147 30∼150 2∼13 TCP＞I
        Spear  et  al.  (1964)   78 30 3 TCP=I
    H i m m e l h o c h  e t  a l  ( 1 9 9 1 )  5 6 3 7 6 T C P ＞I
        Thase  et  al.  (1992)   16 39 6 TCP＞I
  v s .  A m i t r i p t y l i n  ( A )
    R a z a n i  e t  a l .  ( 1 9 8 3 )  5 3 4 0 4 T C P = A
  v s .  N o r t r i p t y l i n  ( N )
        White  et  al.  (1984) 183 44 4 TCP=N＞Pl
  v s .  M o c l o b e m i d  ( M )
        Heinze  et  al.  (1993) 160 10∼30 4 TCP＞M
Legend:  =indicates  equivalent  to,  ＞indicates  more  effective  than  references  in  this  table  are  given  in  detail  in  Laux  et  al.,  2002.
minor  depression  or  dysthymia  (Chaudhuri  et  al., 
2006). Depression in PD is associated with increased 
disability  and  reduced  quality  of  life,  the  impact  of 
depressive  symptoms  in  early  PD  especially  should 
not  be  underestimated  (Ravina  et  al.,  2007).
MAOIs  in  depression
    While  early  studies  suggested  that  MAOIs  were 
not  as  effective  as  other  antidepressants,  more 
recent  studies  have  demonstrated  that,  when  pre-
scribed  in  adequate  dosages,  phenelzine  and 
tranylcypromine  are  as  effective  as  other  anti-
depressants (Pare, 1985). Table 6 gives a summary 
of important controlled studies with tranylcypromine. 
In a recent study tranylcypromine, 60 mg daily, was 
found  effective  in  the  treatment  of  panic  disorder 
and social anxiety disorder comorbidity (Nardi et al., 
2010).
    The  main  indications  for  the  classical  irreversible 
MAOIs  are  subgroups  of  depression  such  as 
atypical  depression,  dysthymia  or  for  patients  who 
do  not  respond  to  reuptake  inhibitors,  so-called 
therapy  resistant  depressions  (Nolen  et  al.,  1994; 
Paykel,  1995;  Bauer  et  al.,  2002).
    The  therapeutic  efficacy  of  moclobemide  has 
been assessed in numerous controlled studies com-
paring it with placebo and established antidepressants 
(for  reviews  see  Laux,  1989;  Fitton  et  al.,  1992; 
Fulton  and  Benfield,  1996;  Laux  et  al.,  2002).  An 
overview  of  the  most  relevant  trials    is  given  in 
Table  7.
    Large  trials  in  patients  with  major  depression 
have  generally  confirmed  that  the  efficacy  of 
moclobemide  is  equivalent  to  that  of  TCAs  beside 
some negative studies. Moclobemide treatment was 
usually  fixed  up  to  300,  400  or  600  mg/day.  It 
should be noted, however, that the use of dosages 
of  up  to  900  mg/d  has  been  established  due  to 
clinical  experience  nowadays  particularly  in  patients 
with refractory depression (Guentert et al., 1995). A 
meta-analysis  of  inpatient  studies  indicated  that 
higher dosages (＞450 mg/day) of moclobemide are 
needed  for  full  therapeutic  effect  in  patients  with 
severe  depression  (Angst  et  al.,  1995).
    Subgroup  analyses  of  patients  revealed  moclo-8 Peter  Riederer
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Table  7.  Randomised,  double-blind  controlled  studies  with  moclobemide  (M)  in  the  treatment  of  depressive  disorders  (selection; 
references  see  Fulton  and  Benfield  1996;  Laux  et  al.,  2002)
Study/Reference N
M-Dosage
(mg/day)
Duration
Response-rate  (%) Adverse
effects M C
  v s .  A m i t r i p t y l i n  ( A )
        Bakish  et  al.  (1992) 82 200∼600 6 56 60 M=PL＜A
        Evans  et  al.  (1992) 48 300∼400 4 49 59 M＜A
  v s .  C l o m i p r a m i n  ( C )
    D i e r i c k  e t  a l .  ( 1 9 9 0 ) 5 3 3 0 0 ∼600 4 43 38 M＜C
        Larsen  et  al.  (1991) 80 300∼600 6 46 72 M＜C
        Guelfi  et  al.  (1992) 103   75∼450 6 66 72 M＜C
        DUAG  (1993) 107 400 6 19 33 M＜C
        Kragh-Sorensen  et  al.  (1995) 142 400 6 51 36 M＜C
        Lecrubier  et  al.  (1995) 191 400∼600 12 63 65 M＜C
        Jouvent  et  al.  (1998) 124 450 4 C＞MM ＜C
  v s .  D o x e p i n  ( D )
        Philipp  et  al.  (1993) 183 400 6 52 44 M＜D
  v s .  I m i p r a m i n  ( I )
        Baumhackl  et  al.  (1989) 325 300∼600 4 58 58 M＜I
        Versiani  et  al.  (1989) 273 300∼600 6 63 68 Pl＜M＜I
        Lecrubier  &  Guelfi  (1990) 291 300∼600 6 M=I M＜I
        Rimon  et  al.  (1993) 113 150∼525 4 71 64 M＜I
        UK  Study  Group  (1994) 106 300∼450 6 M=I=Pl M＜I
  v s .  M a p r o t i l i n  ( M )
        Gachoud  et  al.  (1994) 109 300∼400 4 55 59
  v s .  N o r t r i p t y l i n  ( N )
    N a i r  e t  a l .  ( 1 9 9 5 ) 3 5 1 0 0 ∼400 7 23 33 M=Pl＜N
  v s .  F l u o x e t i n  ( F )
        Williams  et  al.  (1993) 92 300∼600 6 72 59 M=F
        Lonnqvist  et  al.  (1994) 169 300∼450 6 67 57 M=F
        Reynaert  et  al.  (1995) 80 300∼600 6 47 48 M=F
        Lapierre  et  al.  (1997) 121 200∼600 6 M=F M=F
  v s .  S e r t r a l i n e 6 3 3 0 0 ∼600 13 73 42
        Turkcapar  et  al.  (1998) 50 82*
        Sogaard  et  al.  (1999) 197 300∼450 12 68 78
C:  comparator,  =indicates  equivalent  to,  ＞indicates  more  effective/better  tolerated  than.  *melancholic  subtype.
bemide to be effective in patients with dysthymia or 
atypical  depression  especially  (Lonnqvist  et  al., 
1995). 
    Several  trials  have  evaluated  moclobemide  alone 
or  in  combination  with  TCAs  or  SSRIs  in  the 
treatment  of  refractory  depression  (Bakish  et  al., 
1995)  reporting  positive  results.  These  data  are 
limited  and  great  caution  is  necessary  because  of 
the  potential  to  induce  the  serotonin  syndrome 
when  combining  moclobemide  with  serotoninergic 
drugs.
    Uncontrolled  long  term  follow-up  studies  demon-
strated  continued  effectiveness  of  moclobemide 
over the treatment period of 1 year with more than 
60%  of  patients  having  continued  response  (Fulton 
and  Benfield,  1996).  The  role  of  MAOIs  in  mainte-
nance treatment of depression still has to evaluated 
(Kennedy,  1997).
    MAO-B  inhibitors  like  selegiline  in  high  dosage 
have  been  used  in  therapy-refractory  depressions 
probably  due  to  non-selective  MAO  effects  (see 
review Laux, 1993). Recently, transdermal selegiline 
has  been  approved  and  released  in  the  USA  for 
treatment of major depression with a target dose of 
6  mg/24  hours.  This  dosage  and  application  over-
comes  the  MAO-B  selectivity  and  leads  to  MAO-A 
inhibition,  seen  to  be  necessary  for  antidepressive 
effects. In several controlled studies selegiline trans-
dermal system exhibited significant treatment effects 
on  MDD  including  core  depression  symptoms, 
vegetative symptoms and motor retardation (Frampton 
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nation of selegiline and 5-hydroxytryptophan has been 
tested  in  a  pilot  study  and  proved  antidepressant 
efficacy  (Mendlewicz  and  Youdim,  1978).
Treatment  with  antidepressants  and  MAOIs  in 
PD
    The scientific knowledge about the treatment with 
antidepressant  drugs  among  PD  patients  is  nearly 
missing.  A  pharmaco-epidemiological  study  in  Dan-
mark  showed  that  persons  treated  with  antiparkinson 
drugs have higher frequency of antidepressant drug 
treatment than have controls (Brandt-Christensen et 
al.,  2007).  Most  authors  conclude,  that  recommen-
dations for the optimal drug treatment of depression 
in  PD  are  difficult  to  give  (Burn,  2002).  Serotonin 
selective  reuptake  inhibitors  (SSRIs)  are  given 
frequently, the benefit of SSRI treatment in PD has 
not been established, however (Wermuth and Bech, 
2006).
    Thirty-seven  patients  with  early  PD  have  been 
treated  successfully  with  tranylcypromine  (TCP), 
parkinsonian  symptoms  improved  slightly,  follow-up 
after  1.5  years  on  average  revealed  only  slight 
worsening  (Fahn  and  Chouinard,  1998).  No  other 
studies  have  been  reported  with  TCP  so  far.
    Ten patients with PD have been treated success-
fully with moclobemide vs. moclobemide with selegiline 
under  tyramine  restriction  (Steuer  and  Ballering, 
1997).  Sufficient  data  allowing  conclusions  are 
missing.
Dosage  and  administration
    The  recommended  initial  dosage  of    tranylcypro-
mine is 10∼20 mg/day, of moclobemide 300 to 450 
mg/day, given in 2 to 3 divided doses. Subsequent 
dosage  increase  to  a  maximum  of  60  mg/day,  900 
mg/day respectively, are made as clinically indicated 
(Beckmann  and  Laux,  1991;  Fitton  et  al.,  1992). 
Clinical  experience  and  studies  in  the  last  years 
clearly  have  shown  the  necessity  of  higher  dosage 
of  moclobemide  pointing  out  the  lack  of  early 
sufficient  dose-finding  studies.  Recommended  daily 
doses  of  phenelzine  are  30  to  90  mg,  of  isocarbo-
xazid  30  to  60  mg,  respectively.
    Dietary restrictions are essential for tranylcypromine 
(tyramine-rich  food),  unnecessary  for  moclobemide 
taken  at  the  end  of  a  meal.  A  2  week  wash-out 
period  is  required  for  switching  between  tranylcy-
promine  and  other  classes  of  antidepressants,  not 
between  moclobemide  and  other  antidepressants.
    In patients with severe hepatic impairment, trany-
lcypromine  and  moclobemide  dosages  should  be 
reduced  by  one-third  to  one-half  in  such  patients 
(Atkinson  and  Ditman,  1965;  Fitton  et  al.,  1992).
    The  target  dose  of  selegiline  transdermal  (not 
released  in  Europe  so  far)  is  6  mg/24  hours.
Tolerability  and  safety
    The  most  frequent  adverse  effects  of  irreversible 
MAOIs are orthostatic hypotension, sleep disturbances 
and  nervousness/agitation  (Remick  et  al.,  1989). 
The mostly limiting factor in the use of these MAOIs 
is  the  potential  for  dangerous  interactions  with 
tyramine-rich  foods  and  sympathomimetic  and 
serotoninergic substances. Therefore, prescription is 
only  possible  to  patients  being  strongly  compliant 
with  dietary  restrictions.  In  the  case  of  RIMAs  like 
moclobemide there is no need for dietary restrictions. 
For “selegiline transdermal system” tyramine dietary 
restrictions  are  not  needed.  The  incidence  of  the 
most  frequently  reported  adverse  effects  from 
patients  receiving  MAOIs  are  summarised  in  Table 
7.
    Insomnia  and  impotency  in  men  have  been  the 
most  frequent  side  effects  of  TCP  in  patients  with 
early  PD  (Fahn  and  Chouinard,  1998). 
    Unlike  nonselective,  irreversible  MAOIs  and  tricy-
clics,  moclobemide  has  little  effect  on  the  cardio-
vascular system and lacks anticholinergic properties 
associated with TCAs (Moll et al., 1994; Fulton and 
Benfield, 1996). In almost all controlled clinical studies 
comparing  moclobemide  with  TCAs  moclobemide 
showed  clearly  superior  tolerability  (Versiani  et  al., 
1990; Fitton et al., 1992; Fulton and Benfield, 1996). 
Headache,  insomnia  and  agitation  were  the  only 
one side effects being reported more frequently with 
moclobemide  compared  to  re-uptake  inhibiting  anti-
depressants.  Dizziness  and  nausea  have  been 
noticed additionally. No systematic changes in blood 
pressure were observed with moclobemide, whereas 
increases  in  both  blood  pressure  and  pulse  were 
recorded  for  tranylcypromine  (Laux  et  al.,  1996). 
Body  weight  gain  has  been  observed  with  phenel-
zine  and  isocarboxazid,  no  clearcut  cases  with 
tranylcypromine or moclobemide have been reported 
(Cantu  and  Korek,  1988).  Compared  to  SSRIs 10 Peter  Riederer
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moclobemide showed fewer gastrointestinal adverse 
effects  and  sexual  dysfunction  have  not  been 
reported  with  moclobemide  (Philipp  et  al.,  1999).
    Regarding  cognitive  functions  data  in  favour  of 
moclobemide  compared  to  other  antidepressants 
are  available:  Behavioural  toxicity  assessed  by 
choice  reaction  time  is  very  low  or  missing,  psy-
chomotor  functions  seem  not  be  influenced  nega-
tively  perhaps  even  improved  (Hindmarch  et  al., 
1992).
    The principal side effects of selegiline transdermal 
were local dermal reactions and (dose-related) insom-
nia  (Robinson  and  Amsterdam,  2008).
    After  ingestion  of  up  to  20  g  of  moclobemide  no 
fatalities  were  observed,  so  moclobemide  can  be 
considered  as  a  ‘safe’  antidepressant  (DeJonghe 
and Swinkels, 1992; Chen and Ruch, 1993). Several 
fatal  overdoses  have  been  reported  when  moclo-
bemide  was  combined  with  serotoninergic  antidepre-
ssants  like  citalopram,  clomipramine  or  fluoxetine 
due  to  occurrence  of  a  serotonin  syndrome  (Neu-
vonen  et  al.,  1993).  In  contrast,  irreversible  MAOIs 
like  tranylcypromine  must  be  regarded  as  less  safe 
regarding  to  the  fatal  toxicity  index  (Henry  et  al., 
1995).
Side  effects  of  selegiline  and  rasagiline
  Selegiline  is  well  tolerated.  Side  effects/adverse 
reactions like sleeplessness, nausea, vomiting, dizzi-
ness, dry mouth, orthostatic hypotension and dyski-
nesias  have  been  all  observed  in  the  range  of  2∼
5%  of  PD  patients  (Parkinson-Study-Group,  1993; 
Reichmann  et  al.,  2002)  which  is  comparable  to 
placebo.  Other  side  effects  like  headache,  heart 
beating,  dyspnoe,  edema,  confusion,  micturition 
dysfunction,  loss  of  appetite  and  anxiety  are  even 
more rare and below 2% (Reichmann et al., 2002).
    Rasagiline
    Adverse  reactions  as  seen  with  other  dopami-
nergic drugs, like nausea, vomiting, orthostatic hypo-
tension, somnolence, hallucinations and dyskinesias 
are tolerable in most cases. Vomiting was noteable 
at  1  mg/day  in  the  PRESTO-study,  as  was  the 
occurrence  of  dyskinesias  but  such  adverse 
reactions  have  not  been  described  in  other  clinical 
trials like the LARGO-trial. Cognitive and behavioural 
symptoms  of  PD  are  not  changed/worsened  at  1 
mg/day  rasagiline  (Elmer  et  al.,  2006).
    Although  interactions  may  be  suggested  when 
MAO-B inhibitors are combined with COMT-inhibitors, 
such  adverse  reactions  have  not  been  reported  to 
be  of  relevance.  In  fact  rasagiline  is  effective  and 
well  tolerated  in  PD  patients  with  L-DOPA  induced 
motor  fluctuations  receiving  entacapone  (Elmer  et 
al.,  2006).
The  cardiovascular  risk  in  selegiline  and 
rasagiline  treated  PD
    Selegiline  is  metabolized  mainly  to  desmethyl- 
selegiline,  L-amphetamine  and  L-metamphetamine. 
Given  these  facts  there  was  always  a  profound 
discussion  about  the  contribution  of  these  meta-
bolites  to  selegiline’s  clinical  symptomatic  effects 
(Reynolds  et  al.,  1978;  Elsworth  et  al.,  1982)  and 
selegilines  adverse  reactions,  predominantly  of 
cardiovascular  origin  (Churchyard  et  al.,  1997).  L- 
Amphetamine  has  about  a  ten  times  lower  activity 
on  the  peripheral  sympathetic  system  compared  to 
D-amphetamine.  On  the  other  hand,  both  are 
equipotent  in  blocking  striatal  dopamine  uptake 
(Coyle and Snyder, 1969). A clinical trial of daily 10 
mg  selegiline  vs.  the  calculated  dosis  and  ratio  of 
L-amphetamine  and  L-  metamphetamine  in  PD 
patients  came  to  the  conclusion  that  selegiline  did 
show  antiakinetic  efficacy  while  the  metabolites  did 
not  (Elsworth  et  al.,  1982).  Therefore,  selegiline  is 
not  acting  via  the  amphetamine  metabolites.  Also, 
from  the  side  effect  profile  as  reported  in  the  large 
selegiline  based  trials  there  is  no  evidence  for 
enhanced  cardiovascular  risk  (eg.  Parkinson  Study 
Group,  1989;  1993).  This  holds  true  also  when 
selegiline  is  compared  to  treatment  based  on 
L-DOPA  and  dopaminergic  receptor  agonists. 
However,  head-to  head  comparison  is  missing.
    Nevertheless,  to  avoid  further  such  discussion  a 
sublingual  galenic  form  of  selegiline  treatment  has 
been  developed  named  Zydis-selegiline  (Clarke  et 
al., 2003a; 2003b). This “melting-tablet” avoids a first- 
pass  effect  and  therefore  a  significant  break-down 
to  L-amphetamine  and  L-metamphetamine  in  the 
range  of  90%.  A  reduction  of  the  daily  dosis  of  10 
mg selegiline to 1, 25 mg selegiline is advised. The 
bioavailability  of  selegiline  when  given  as  “melting- 
tablet” is more homogene and better reproduceable 
compared  to  the  peroral  type  of  application  (Clarke 
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galenic  form  of  selegiline  has  been  developed  for 
the  treatment  of  major  depression  again  reducing 
selegilines  first-pass  biotransformation  (Frampton 
and  Plosker,  2007;  Robinson  et  al.,  2007). 
    Melting  tablet  and  transdermal  selegiline  avoid 
first-pass  metabolism,  cause  higher  drug  availability 
in MAO-B preferring organs and reduce the concen-
tration  of  metabolites.  Increased  drug  concentration 
may cause significant inhibition of both MAO-B and 
−A  in brain  but not  in  the periphery. This  explains 
selegilines  antidepressant  activity  when  combined 
with  5-hydroxytryptophan  without  the  cheese-effect 
and  without  the  serotonin  syndrome  (Mendlewicz 
and  Youdim,  1978).
    Under  clinical  conditions  selegiline  is  not  more 
“toxic” than other dopaminergic treatment strategies. 
In  fact  the  side  effect  and  adverse  reaction  profile 
of  selegiline  has  been  evaluated  as  being  well 
tolerated and “mild” compared to other PD treatment 
strategies,  eg.  orthostatic  reactions  have  been 
noteable  in  only  3,  7%  of  patients  (Reichmann  et 
al.,  2002).
    It  should  be  mentioned  that  L-amphetamine  is  in 
clinical  use  for  the  treatment  of  attention-deficit- 
hyperactivity  syndrome  (ADHD)  without  major  side 
effects.  In  line  with  this  are  several  studies  as 
summarized  by  Reidenberg  (1994)  showing  no 
abuse  liability  of  selegiline.
    The  contribution  of  desmethylselegiline  (DMS)  to 
the  effects  of  selegiline  has  been  underestimated 
so  far.  DMS  is  a  weak  inhibitor  of  MAO-B  and 
seems to have glutathione related properties (Heinonen, 
1997;  Heinonen  et  al.,  1997).
    In  contrast  to  selegiline,  rasagiline  is  not  meta-
bolized  to  amphetamine.  The  main  metabolite  of 
rasagiline is aminoindan. Therefore any cardiovascular 
responses of rasagiline are neglectible as shown in 
animal  studies  (Finberg  et  al.,  2006)  and  in  all 
clinical  trials  including  the  TEMPO-  (Parkinson 
Study  Group,  2002),  PRESTO-  (Parkinson  Study 
Group,  2005),  LARGO-  (Rascol  et  al.,  2005)  and 
ADAGIO-study  (Olanow  et  al.,  2008;  2009).
    In  the  recommended  therapeutic  dosis  of  1  mg/ 
day  rasagiline  does  not  potentiate  the  tyramine 
induced  cheese-effect  (de  Marcaida  et  al.,  2006). 
This is in agreement with earlier findings in rats and 
cats (Finberg et al., 1981; Chen and Swope, 2005; 
Finberg  et  al.,  2006).
Drug  interactions
    Coadministration  of  SSRIs  and  other  serotoni-
nergic  substances  to  tranylcypromine  is  contraindi-
cated  due  to  the  risk  of  serotonin  syndrome.  With 
moclobemide  great  caution  should  be  exercised 
with  this  combination.  Severe,  sometimes  fatal, 
interactions between nonselective, irreversible MAOIs, 
moclobemide  as  well  as  selegiline  and  pethidine 
and  dextromethorphan  have  been  reported.  Indirectly 
acting  sympathomimetics  (tyramine,  ephedrine, 
pseudoephedrine)  should  be  administered  with 
caution in patients treated with MAOIs (Dingemanse, 
1993).
    The  elimination  of  moclobemide  is  significantly 
reduced  by  cimetidine  making  dose  adjustment 
necessary.
    Although  selegiline  has  been  reported  to  have 
antidepressant actions when combined with 5-hydroxy-
tryptophan (Mendlewicz and Youdim, 1978) MAO-B- 
inhibitors  may  not  be  safe  enough  to  avoid  the 
“serotonin-syndrome”  when  given  in  adjunct  to 
serotonin-reuptake inhibitors (SSRIs) to treat depre-
ssion and anxiety in PD patients. However, there is 
a  low  risk  (0,  24%)  to  develop  the  “serotonin- 
syndrome”  in  selegiline  treated  patients  (Richard  et 
al., 1997). Also the results of a small number of PD 
patients  treated  with  tricyclics  and  SSRIs  plus 
rasagiline  in  the  TEMPO-,  PRESTO-  and  LARGO- 
studies  do  not  give  evidence  for  the  “serotonin- 
syndrome”,  the  population  incidence  of  serotonin 
toxicity  in those  patients  has  a  9,  5%  probability  of 
being  less  than  1,  2%  (Pannisset  et  al.,  2007; 
Montgomery  and  Panisset,  2009).  However,  a 
clinical trial with a biostatistic power relevant to give 
a  definite  answer  to  the  problem  is  missing. 
Therefore  MAO-B  inhibitors  have  not  to  be  com-
bined  with  drugs  stimulating  the  serotoninergic 
system.
    Meperidin plus selegiline has been reported to be 
dangerous  as  it  causes  severe  hypertension 
(Zornberg  et  al.,  1991).
    Selegiline  transdermal  without  tyramine  restriction 
revealed  no  acute  hypertensive  reactions  in  trials, 
until  more  data  are  available,  foods  that  are  rich 
sources  of  tyramine  should  be  avoided,  however. 
    As  described  by  Chen  and  Swope  (2005) 
CYP1A2 inhibitors (cimetidine, fluvoxamine, ciproflo-
xacin)  increase  the  area  under  curve  of  rasagiline, 12 Peter  Riederer
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while  CYP1A2  inducers  like  omeprazol  decrease  it, 
as  it  may  decrease  in  heavy  smokers.
    Minor time-dependent mechanism-based inhibition 
of  CYP2D6  has  been  described  for  selegiline  and 
moclobemid  in  experimental  designs;  the  significance 
in human beings remains to be investigated (Polasek 
et  al.,  2006).  For  selegiline  interactions  with  CYP 
3A4  and  CYP  2E1  may  be  relevant  too.
Expert  commentary
    While  selective  MAO-B-inhibitors  demonstrate  a 
significant benefit in PD and improve motoricity and 
motor  fluctuations  eventually  causing  disease-modi-
fication  in  general  MAOIs  to  date  play  a  subor-
dinate  therapeutic  role  in  the  treatment  of  depre-
ssion  in  PD  compared  to  SSRIs  or  reboxetine,  a 
selective noradrenergic reuptake inhibitor. This attitude 
is  primarily  due  to  the  risk  of  adverse  effects  and 
compliance problems (e.g. dietary restrictions, inter-
action problems) with MAOIs. Moclobemide according 
to  its  favourable  adverse  effect,  interaction  and 
toxicity  profile  can  be  used  in  depressed  Parkinson 
patients  when  activating  properties  are  necessary, 
especially. 
    Overall, the clinical use of MAOIs may be limited 
by the possible adverse effects of restlessness and 
insomnia  -  but  see  rasagiline.  As  far  as  long  term 
and  prophylactic  treatments  are  concerned,  the 
place  of  MAOIs  still  has  to  be  verified  as  anti-
depressant  or  antidementive  drugs  in  PD  (Tariot  et 
al.,  1987;  Sano  et  al.,  1997;  Filip  and  Kolibas, 
1999;  Sterling  et  al.,  2002;  Elmer  et  al.,  2006; 
Carageorgiou  et  al.,  2008).  Controlled  studies  are 
urgent  needed  for  final  evaluation  and 
recommendations.
Five-year  view
    It  would  be  worthwile  to  perform  clinical  studies 
to demonstrate the capacity of MAO-B inhibitors as 
antidepressants  and  antidementive  drugs.  New 
substances  like  ladostigil  (MAOA/B  inhibitor;  AchE- 
inhibitor)  or  M30  and  HLA-20  (MAO-A/B  inhibitor, 
iron-chelator) and M30P (MAO-A/B inhibitor,  carbonate 
cholinesterase inhibitor) give future aspects of using 
MAO-I’s  in  a  variety  of  clinical  indications  (Weinreb 
et  al.,  2010).  The  pharmacological  properties  of 
aminoindan  have  to  be  elucidated  as  they  may  be 
neuroprotective  (Bar-Am  et  al.,  2010).
Key  issues
    Head-to-head  clinical  trials  are  necessary  to 
demonstrate  disease-modification  using  improved 
delayed-start-study  designs  with  selegiline  and 
rasagiline.  Otherwise  no  objective  comparison  can 
be  made  between  the  neuroprotective/neurorestaurative 
properties  of  selegiline  and  rasagiline.
    Aminoindan  has  to  be  tested  in  vivo  in  order  to 
get  insight  into  its  anti-parkinsonian  efficacy.
    The  many  molecular  biological  and  -genetic  data 
evolved  from  in-vitro  studies  have  to  be  confirmed 
in in-vivo experiments to prove relevance in human 
beings.  That  other  MAO-Is,  even  reversible  ones 
might  well  be  important  in  neuroprotection/disease 
modification  is  a  just  ongoing  important  issue.  In 
addition,  the  respective  role  of  MAO-A  has  to  be 
elucidated  in  more  detail.
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